Transcatheter arterialization of the deep veins for chronic limb-threatening ischemia in no-option patients kept most ...

Q3 2025 Earnings Call Transcript October 29, 2025 BridgeBio Pharma, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and the enVVe IDE study- Cash burn of $4.2 million in Q3 remains in line with ...